NCT06998173View on ClinicalTrials.gov

Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

July 30, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

DAT-1604 tablet

DAT-1604, a potent and selective oral small molecule inhibitor of DNA Polymerase θ (Pol θ).

Trial Locations (1)

100021

Cancer Hostital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

Sponsors
All Listed Sponsors
lead

Danatlas Pharmaceuticals Co., Ltd

INDUSTRY

NCT06998173 - Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor | Biotech Hunter | Biotech Hunter